Featured Articles
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. (opens new window)
Source: Lancet 2024;403(10423):249-60.
Indexed: PubMed 38048786
DOI: 10.1016/S0140-6736(23)01724-5
https://pubmed.ncbi.nlm.nih.gov/38048786/ (opens new window)
Medical Information Packets
Clinical Strategies
Medicine and Surgery
Clinical strategies for managing hemorrhage and anemia without allogeneic blood transfusion.
Pediatrics
Clinical strategies for managing neonatal and pediatric patients without allogeneic blood transfusion.
Diseases and Conditions
Clinical strategies for managing specific diseases or conditions without allogeneic blood transfusion.
Bioethics and Law
Ethical, legal, and social factors for health-care professionals to consider when treating Jehovah’s Witnesses.
Videos
Contact Local Representative
Contact local representatives who provide free assistance to clinicians treating Jehovah’s Witnesses.